Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| 1 |
Qualcomm
QCOM
|
+$701M |
| 2 |
Alibaba
BABA
|
+$582M |
| 3 |
Goldman Sachs
GS
|
+$496M |
| 4 |
Microsoft
MSFT
|
+$372M |
| 5 |
Halliburton
HAL
|
+$286M |
Top Sells
| 1 |
Walt Disney
DIS
|
+$665M |
| 2 |
Kroger
KR
|
+$551M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$528M |
| 4 |
Novo Nordisk
NVO
|
+$457M |
| 5 |
Morgan Stanley
MS
|
+$418M |
Sector Composition
| 1 | Consumer Discretionary | 19.69% |
| 2 | Technology | 18.08% |
| 3 | Healthcare | 16.2% |
| 4 | Communication Services | 11.92% |
| 5 | Financials | 9.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
476
Spyre Therapeutics
SYRE
$1B
| $9.13M | 0.01% |
56,998
+1,475
| +3% | +$236K |
|
477
Agios Pharmaceuticals
AGIO
$2.12B
| $8.94M | 0.01% |
169,252
-722
| -0.4% | -$38.1K |
|
|
ZEN
478
DELISTED
ZENDESK INC
ZEN
| $8.78M | 0.01% |
285,867
-22,844
| -7% | -$702K |
|
|
NBLX
479
DELISTED
Noble Midstream Partners LP
NBLX
| $8.43M | 0.01% |
+302,238
| New | +$8.43M |
|
480
Marcus & Millichap
MMI
$1.28B
| $8.42M | 0.01% |
322,001
-41,305
| -11% | -$1.08M |
|
481
MPLX
MPLX
$51.1B
| $8.4M | 0.01% |
247,966
+71,936
| +41% | +$2.44M |
|
|
MPG
482
DELISTED
Metaldyne Performance Group Inc.
MPG
| $8.13M | 0.01% |
513,123
-114,883
| -18% | -$1.82M |
|
483
Foot Locker
FL
$2.29B
| $8.02M | 0.01% |
+118,462
| New | +$8.02M |
|
484
Salarius Pharmaceuticals
SLRX
$2.37M
| $7.99M | 0.01% |
9
| – | – |
|
485
Chemours
CC
$2.43B
| $7.9M | 0.01% |
+493,645
| New | +$7.9M |
|
|
CORE
486
DELISTED
Core Mark Holding Co., Inc.
CORE
| $7.66M | 0.01% |
+213,823
| New | +$7.66M |
|
|
AVXS
487
DELISTED
AveXis, Inc. Common Stock
AVXS
| $7.55M | 0.01% |
183,145
+3,362
| +2% | +$139K |
|
|
FENX
488
DELISTED
Fenix Parts, Inc.
FENX
| $7.16M | 0.01% |
1,807,324
-169,647
| -9% | -$672K |
|
|
CMRX
489
DELISTED
Chimerix, Inc.
CMRX
| $7.07M | 0.01% |
1,276,937
-5,667
| -0.4% | -$31.4K |
|
490
Jazz Pharmaceuticals
JAZZ
$7.88B
| $6.92M | 0.01% |
56,937
-549,083
| -91% | -$66.7M |
|
491
USA Compression Partners
USAC
$2.84B
| $6.9M | 0.01% |
367,189
+6,888
| +2% | +$129K |
|
492
Energy Transfer Partners
ET
$58.9B
| $6.67M | 0.01% |
+397,234
| New | +$6.67M |
|
|
DSCI
493
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $6.58M | 0.01% |
1,409,668
-3,866
| -0.3% | -$18.1K |
|
|
KITE
494
DELISTED
Kite Pharma, Inc.
KITE
| $6.42M | 0.01% |
+114,879
| New | +$6.42M |
|
495
Exelixis
EXEL
$10.1B
| $6.4M | 0.01% |
+500,000
| New | +$6.4M |
|
|
LJPC
496
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $6.13M | 0.01% |
257,709
+5,272
| +2% | +$125K |
|
497
BioCryst Pharmaceuticals
BCRX
$1.72B
| $5.96M | 0.01% |
1,351,330
-4,972
| -0.4% | -$21.9K |
|
498
MacroGenics
MGNX
$111M
| $5.84M | 0.01% |
195,111
-1,051
| -0.5% | -$31.4K |
|
499
Norfolk Southern
NSC
$61.8B
| $5.82M | 0.01% |
59,978
-571
| -0.9% | -$55.4K |
|
500
Syndax Pharmaceuticals
SNDX
$1.41B
| $5.82M | 0.01% |
383,776
-153,769
| -29% | -$2.33M |
|